BioSpace News Archive

Aerovate Therapeutics, Inc. today announced financial results for the quarter ended September 30, 2022, and recent business highlights.

SELLAS Life Sciences Group, Inc. today announced important updates relating to its ongoing Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients).

EVERSANA ®, a pioneer of next-generation commercial services to the global life sciences industry, today named Sy Pretorius as the company’s new Chief Operating Officer and President, Outsourced Solutions.

Revolo Biotherapeutics announced that it will be participating in the TIDES Europe 2022 Conference on Oligonucleotide & Peptide Therapeutics, being held virtually and in-person in Vienna, Austria, from November 16-18.

MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors meeting, Nov. 16-19 in Nashville, Tenn.

Cocrystal Pharma, Inc. reports financial results for the three and nine months ended September 30, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”) today reported financial results for the third quarter ended September 30, 2022 and provided an update on the company’s business and clinical development progress.

Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334).